Sling Therapeutics to Participate in Upcoming Investor Conferences

2023-11-08

临床2期

ANN ARBOR, Mich., Nov. 8, 2023 /PRNewswire/ -- Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), will be participating in three upcoming investor conferences in November 2023. Details of the presentations can be found below.

Stifel 2023 Healthcare Conference

Chief Executive Officer, Ryan Zeidan, Ph.D., will present a company presentation and host 1x1 investor meetings on Tuesday, November 14, at 9:45 a.m. ET.

BTIG 3rd Annual Ophthalmology Day

Chief Executive Officer, Ryan Zeidan, Ph.D., will present a company presentation and host 1x1 investor meetings on Monday, November 27, at 3:30 p.m. ET.

Piper Sandler Healthcare Conference

Chief Executive Officer, Ryan Zeidan, Ph.D., will present a company presentation and host 1x1 investor meetings on Wednesday, November 29, at 9:50 a.m. ET.

About Sling Therapeutics

Sling Therapeutics, Inc., is a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED). The company is advancing the evaluation of its lead product candidate, linsitinib, in a Phase 2b clinical trial based on extensive preclinical and clinical data. Linsitinib offers the potential of a convenient oral small molecule that could significantly reduce the treatment burden for people living with TED. For more information visit https://slingtx.com/.

Investor Contact

Jessica Vo

Gilmartin Group, LLC

[email protected]

Media Contact

Adam Daley

Berry & Company Public Relations

212.253.8881

[email protected]

SOURCE Sling Therapeutics

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。